On May 15, 2026, James O. Hearty, the Chief Compliance Officer at DaVita Inc. (NASDAQ:DVA), executed a sale of 15,000 shares of common stock. This transaction represented a total divestment value of approximately $2.91 million. The selling price for these shares varied between $193.36 and $199.84, resulting in a weighted average sale price calculated at $193.983 per share.
This recent stock transaction followed a substantial corporate action on the preceding day. On May 14, 2026, Mr. Hearty exercised 5,784 Stock Appreciation Rights (SARs). These SARs were originally granted on March 15, 2022, and were scheduled to vest in two equal installments: one on March 15, 2025, and the second on March 15, 2026. The exercise price for these rights was set at $110.63 per share.
The act of exercising the SARs allowed Mr. Hearty to acquire 5,784 shares of DaVita common stock. Based solely on the stated exercise price, the value attributed to these newly acquired shares totaled $639,883. To facilitate this acquisition, two withholding mechanisms were utilized. First, 3,231 shares were withheld, amounting to approximately $640,061, which covered the base price of the SARs. Second, an additional 1,117 shares were reserved and withheld to satisfy required tax obligations, valued at roughly $221,277. The share price used for these withholding calculations was $198.10.
Following both the exercise of the rights and the subsequent sale, Mr. Hearty's direct ownership stake in DaVita common stock increased to 22,389 shares. This reported activity occurred while DaVita’s stock price was trading near its 52-week high of $202.69. Notably, this level reflects a significant gain for the company over the preceding six months, achieving a remarkable 71% increase in value.
Analysis of Company Performance and Market Reaction
The timing of these insider transactions coincides with robust financial disclosures from DaVita Inc. The company reported strong first-quarter earnings for 2026. Earnings per share (EPS) were recorded at $2.87, a figure that substantially exceeded the consensus forecast of $2.32. Furthermore, the revenue generated also surpassed market expectations, reaching $3.42 billion compared to an anticipated $3.34 billion.
This strong first-quarter performance prompted immediate and positive responses from major financial institutions. Deutsche Bank reacted positively to the revenue beat by upgrading DaVita’s stock rating. The firm revised its rating from Hold to Buy, simultaneously setting a new price target of $220, an increase from the previous target of $126. Separately, BofA Securities also adjusted its outlook, raising its price target for DaVita to $145 from $130, although the firm maintained an Underperform rating.
The positive momentum was further fueled by operational metrics. In the first quarter, the revenue generated per treatment amounted to $417.59. This figure not only exceeded Wall Street estimates by $8.30 but also represented a 4.4% increase when compared year-over-year. These developments collectively signal strong financial health and positive analyst sentiment surrounding DaVita's operations, prompting the company itself to raise its guidance, albeit with a conservative approach.
Key Takeaways and Market Implications
- Insider Selling Activity: The Chief Compliance Officer's sale of over $2.9 million worth of stock introduces a point of caution regarding internal confidence.
- Conservative Guidance Adjustment: Despite strong performance, the company raised its guidance in a cautious manner, which could temper future expectations.